De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study

[1]  R. Gelber,et al.  Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[2]  H. Kuerer,et al.  Expanding Implementation of ACOSOG Z0011 in Surgeon Practice , 2018, Clinical breast cancer.

[3]  A. Giuliano,et al.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial , 2017, JAMA.

[4]  G. Nieuwenhuijzen,et al.  Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era , 2017, Annals of surgery.

[5]  P. V. van Diest,et al.  A Novel Less‐invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node‐positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study , 2017, Clinical breast cancer.

[6]  H. Kuerer,et al.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Thabane,et al.  A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer , 2016, Annals of Surgical Oncology.

[8]  H. Cody,et al.  Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases , 2016, Annals of Surgical Oncology.

[9]  G. Nieuwenhuijzen,et al.  Patterns of Care in the Administration of Neo‐adjuvant Chemotherapy for Breast Cancer. A Population‐Based Study , 2016, The breast journal.

[10]  G. Hortobagyi,et al.  Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. , 2016, JAMA oncology.

[11]  A. Soran,et al.  Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes , 2016, Annals of Surgical Oncology.

[12]  R. Beets-Tan,et al.  The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  C. Gross,et al.  Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States , 2015, Cancer.

[14]  M. Morrow,et al.  The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation , 2015, Annals of Surgical Oncology.

[15]  P. V. van Diest,et al.  Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. , 2015, European journal of cancer.

[16]  E. Rutgers,et al.  Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. , 2015, Annals of surgery.

[17]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[18]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[19]  J. Boughey,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases: commentary on the IBCSG 23-01 Trial. , 2013, Gland surgery.

[20]  C. V. D. van de Velde,et al.  Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  A. Luini,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. , 2013, The Lancet. Oncology.

[22]  L. Strobbe,et al.  Axillary Recurrence After a Tumor-Positive Sentinel Lymph Node Biopsy Without Axillary Treatment: A Review of the Literature , 2012, Annals of Surgical Oncology.

[23]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[24]  H. Kuerer,et al.  Trends in and Outcomes from Sentinel Lymph Node Biopsy (SLNB) Alone vs. SLNB with Axillary Lymph Node Dissection for Node-Positive Breast Cancer Patients: Experience from the SEER Database , 2010, Annals of Surgical Oncology.

[25]  Talia K. Ben-Jacob,et al.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial , 2010, Annals of surgery.

[26]  Kelly K. Hunt,et al.  Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. , 2010, Annals of surgery.

[27]  M. Ross,et al.  Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients , 2009, Annals of surgery.

[28]  A. Rademaker,et al.  Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. , 2009, Journal of Clinical Oncology.

[29]  J A Knottnerus,et al.  Completeness of cancer registration in Limburg, The Netherlands. , 1993, International journal of epidemiology.

[30]  J. Boughey.  Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy, by Dengel et al. , 2013, Annals of Surgical Oncology.

[31]  G. Plitas,et al.  Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy , 2013, Annals of Surgical Oncology.